Pembrolizumab/carboplatin/pemetrexedLack of efficacy and fulminant type-1 diabetes: case report

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2021年 / 1852卷 / 1期
关键词：
D O I：
10.1007/s40278-021-94811-9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：358 / 358
相关论文
共 50 条
  • [41] Pembrolizumab/carboplatin/paclitaxelArthralgia of the hands and lack of efficacy: case report
    Reactions Weekly, 2022, 1927 (1) : 447 - 447
  • [42] Cisplatin/pemetrexedLack of efficacy: case report
    Reactions Weekly, 2024, 2034 (1) : 106 - 106
  • [43] A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer
    Tang, Yan
    Zhao, Zhe
    Wang, Xinfeng
    Zuo, Wei
    Zhang, Bo
    Yuan, Tao
    Fu, Yong
    IMMUNOTHERAPY, 2021, 13 (06) : 483 - 490
  • [44] Gefitinib/pemetrexedLack of efficacy : case report
    Reactions Weekly, 2024, 2018 (1) : 215 - 215
  • [45] Fulminant type 1 diabetes with Shock rescue: a case report
    Hongliang Dong
    Yingying Ding
    Jiawei Lai
    Linfeng Yu
    Xiaoyuan Shen
    Endocrine, 2024, 84 : 350 - 354
  • [46] Fulminant type 1 diabetes with Shock rescue: a case report
    Dong, Hongliang
    Ding, Yingying
    Lai, Jiawei
    Yu, Linfeng
    Shen, Xiaoyuan
    ENDOCRINE, 2024, 84 (02) : 350 - 354
  • [47] Cisplatin/pemetrexedLack of efficacy: case report
    Reactions Weekly, 2023, 1953 (1) : 147 - 147
  • [48] Cisplatin/pemetrexedLack of efficacy: case report
    Reactions Weekly, 2023, 1941 (1) : 145 - 145
  • [49] Nedaplatin/pemetrexedLack of efficacy: case report
    Reactions Weekly, 2022, 1919 (1) : 452 - 452
  • [50] Gefitinib/pemetrexedLack of efficacy: case report
    Reactions Weekly, 2022, 1930 (1) : 275 - 275
12345